Physician profile
Walter Rivera
NPI 1609886969
$2,254.73
in general payments reported to CMS, 2019-2025
9 companies · $65.58 in 2025
The $65.58 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $224 · 2021: $1,030 · 2022: $289 · 2023: $242 · 2024: $226 · 2025: $65.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527 · Education: $6.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.07 |
| Education | $6.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $912.52 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Medtronic, INC. | $800.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.66 | 2019-2025 | Jardiance |
| Eli Lilly Export S.A. Puerto Rico Branch | $208.53 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $41.29 | 2023-2024 | Eliquis |
| Abbvie INC. | $25.99 | 2020 | |
| Pbg Puerto Rico LLC | $12.69 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.80 | 2022 | |
| Pfizer Pharmaceuticals LLC | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.